IN.PACT Admiral 药物涂层球囊在中国患者中的 IN.PACT SFA 临床研究
IN.PACT SFA China 是一项单臂、独立裁定、前瞻性上市前研究,纳入 143 例中国股浅动脉和/或近端腘动脉原发或再狭窄病变患者,评估 IN.PACT Admiral 药物涂层球囊的安全性和有效性。30 天主要安全终点达 99.3%,1 年一期通畅率 90.9%,免于临床驱动靶病变血运重建率 97.1%,Rutherford 分级显著改善。
要点
- 30 天主要安全终点为 99.3%,1 年一期通畅率 90.9%。
- 1 年免于 CD-TLR 为 97.1%,CD-TLR 率仅 2.9%。
- 尽管病变复杂(平均长度 10.4 cm,52.4% 为 CTO),结果仍良好。
核心结论
- IN.PACT Admiral DCB 在中国患者中 12 个月内显示高通畅率和低 CD-TLR 率,与其它 IN.PACT DCB 试验结果一致。
研究设计与样本
- 单臂、独立裁定、前瞻性上市前研究,纳入 143 例患者(平均年龄 66.8±7.7 岁;107 例男性),来自 15 个中心。
- 病变位于股浅动脉和/或近端腘动脉,包括原发和再狭窄病变。
主要发现
- 30 天主要安全终点(免于器械/手术相关死亡、主要靶肢体截肢和 CD-TLR 的复合终点)为 99.3%。
- 12 个月随访依从性 92.6%;Kaplan-Meier 估计 1 年一期通畅率 90.9%,免于 CD-TLR 97.1%。
- 12 个月 CD-TLR 率为 2.9%;Rutherford 分级从基线到 12 个月显著改善(p<0.001)。
关键数值与推荐
- 平均病变长度 10.4±6.51 cm;52.4%(75 例)为慢性完全闭塞;46.2%(66 例)存在钙化。
- 高血压 104 例(72.7%),糖尿病 66 例(46.2%);Rutherford 2 级 69 例(48.3%),3 级 55 例(38.5%),4 级 19 例(13.3%)。
临床怎么用
- 对于中国股浅动脉和/或近端腘动脉原发或再狭窄病变患者,IN.PACT Admiral DCB 可作为安全有效的治疗选择。
- 即便病变复杂(长病变、CTO、钙化),12 个月结果仍支持使用该 DCB。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To confirm the safety and effectiveness of the IN.PACT Admiral drug-coated balloon (DCB) as a treatment for de novo and native artery restenotic lesions in the superficial femoral artery (SFA) and/or proximal popliteal artery in Chinese subjects. Materials and Methods: IN.PACT SFA China (ClinicalTrials.gov identifier NCT02118532) was a single-arm, independently adjudicated, prospective, premarket study that enrolled 143 subjects (mean age 66.8±7.7 years; 107 men) at 15 centers. The predominant risk factors were hypertension (104, 72.7%) and diabetes mellitus (66, 46.2%). The majority of subjects were classified as Rutherford category 2 or 3 [69 (48.3%) and 55 (38.5%), respectively]; 19 (13.3%) subjects had critical limb ischemia (Rutherford category 4). The mean lesion length was 10.4±6.51 cm; more than half of the lesions (75, 52.4%) were chronic total occlusions. Calcification was found in 66 (46.2%) lesions. Outcomes at 12 months were compared with DCB safety and effectiveness performance goals derived from the literature. The 30-day primary safety outcome was a composite of freedom from device- and procedure-related mortality, major target limb amputation, and clinically-driven target lesion revascularization (CD-TLR). Results: The primary safety outcome was 99.3% at 30 days. Follow-up compliance at 12 months was 92.6%. Estimated 1-year primary patency using Kaplan-Meier analysis was 90.9% and freedom from CD-TLR was 97.1%. The rate of CD-TLR at 12 months was 2.9%. The Rutherford category status improved significantly (p<0.001) between baseline and 12 months. Conclusion: Results from IN.PACT SFA China demonstrated high rates of patency and low rates of CD-TLR in Chinese subjects through 12 months despite patient and lesion complexity. These data are consistent with the results of other IN.PACT DCB trials.
引用
- Chen Z, Guo W, Jiang W, et al. IN.PACT SFA Clinical Study Using the IN.PACT Admiral Drug-Coated Balloon in a Chinese Patient Population. J Endovasc Ther. 2019. PMID: 31204595. doi:10.1177/1526602819852084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。